To address the issues of multidrug-resistance and newly emerging pathogens DeepDrug is developing computer aided drug design software utilizing Artificial Intelligence (AI)-based techniques that access very large datasets and, in turn, creates an improved method for identify new compounds rapidly thereby dramatically shortening the developmental time line and the cost to have a new drug accepted. The software the DeepDrug team has developed is collectively referred to as DeepDrug which is comprised of the lead program eSynth (creates new molecules for a researcher's use) together with eMolFrag (decomposes organic compounds into non-redundant fragments) and eToxPred (predicts the possible side effects.). eDrugRes, an AI based module allows the examination of the genomes of pathogens, etc. to aid in developing new compounds.